RT Journal Article
SR Electronic
T1 Inferring time-varying generation time, serial interval and incubation period distributions for COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.05.22278461
DO 10.1101/2022.08.05.22278461
A1 Chen, Dongxuan
A1 Lau, Yiu Chung
A1 Xu, Xiao-Ke
A1 Wang, Lin
A1 Du, Zhanwei
A1 Tsang, Tim K.
A1 Wu, Peng
A1 Lau, Eric H. Y.
A1 Wallinga, Jacco
A1 Cowling, Benjamin J.
A1 Ali, Sheikh Taslim
YR 2022
UL http://medrxiv.org/content/early/2022/08/06/2022.08.05.22278461.abstract
AB Background The generation time distribution, reflecting the time between successive infections in transmission chains, is one of the fundamental epidemiological parameters for describing COVID-19 transmission dynamics. However, because exact infection times are rarely known, it is often approximated by the serial interval distribution, reflecting the time between illness onsets of infector and infectee. This approximation holds under the assumption that infectors and infectees share the same incubation period distribution, which may not always be true.Methods We analyzed data on observed incubation period and serial interval distributions in China, during January and February 2020, under different sampling approaches, and developed an inferential framework to estimate the generation time distribution that accounts for variation over time due to changes in epidemiology, sampling biases and public health and social measures.Results We analyzed data on a total of 2989 confirmed cases for COVID-19 during January 1 to February 29, 2020 in Mainland China. During the study period, the empirical forward serial interval decreased from a mean of 8.90 days to 2.68 days. The estimated mean backward incubation period of infectors increased from 3.77 days to 9.61 days, and the mean forward incubation period of infectees also increased from 5.39 days to 7.21 days. The estimated mean forward generation time decreased from 7.27 days (95% confidence interval: 6.42, 8.07) to 4.21 days (95% confidence interval: 3.70, 4.74) days by January 29. We used simulations to examine the sensitivity of our modelling approach to a number of assumptions and alternative dynamics.Conclusions The proposed method can provide more reliable estimation of the temporal variation in the generation time distribution, enabling proper assessment of transmission dynamics.Competing Interest StatementB.J.C. consults for AstraZeneca, Fosun Pharma, GSK, Moderna, Pfizer, Roche, and Sanofi Pasteur. The remaining authors declare no competing interests.Funding StatementThis project was supported by the Health and Medical Research Fund (project no. 20190712); a commissioned grant from the Health and Medical Research Fund from the Government of the Hong Kong Special Administrative Region; The Collaborative Research Scheme (Project No. C7123-20G) of the Research Grants Council of the Hong Kong SAR Government; and AIR@InnoHK administered by Innovation and Technology Commission. The funding bodies had no role in study design, data collection and analysis, preparation of the manuscript, or the decision to publish.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Our study received ethical approval from the Institutional Review Board of the University of Hong Kong.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data used in the analysis will be available at Github (on acceptance): https://github.com/DxChen0126/ https://github.com/DxChen0126/ All the data used in the analysis will be available at Github (on acceptance): https://github.com/DxChen0126/ https://github.com/DxChen0126/